HHS Public Access Author manuscript Author Manuscript
Mucosal Immunol. Author manuscript; available in PMC 2016 July 27. Published in final edited form as: Mucosal Immunol. 2016 May ; 9(3): 821–833. doi:10.1038/mi.2015.145.
Distinct genital tract HIV-specific antibody profiles associated with tenofovir gel D Archary#1, KE Seaton#2, JS Passmore1,3,4, L Werner1, A Deal2, LJ Dunphy5, KB Arnold5, NL Yates2, DA Lauffenburger5, P Bergin6, LJ Liebenberg1, N Samsunder1, MW Mureithi7, M Altfeld8, N Garrett1, Q Abdool Karim1,9, SS Abdool Karim1,9, L Morris1,4, and GD Tomaras2,10
Author Manuscript
1Centre
for the AIDS Program of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa.
2Duke
Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
3Institute
of Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town, South Africa. 4National
Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa.
5Department
of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
Author Manuscript
6Imperial
College, International AIDS Vaccine Initiative Core Immune Monitoring Laboratory, London, UK. 7KAVI
Institute of Clinical Research, School of Medicine, College of Health Sciences, University of Nairobi, Nairobi, Kenya
8Heinrich-Pette
Institut, Leibniz Institute for Experimental Virology, University of Hamburg, Hamburg, Germany.
9Department
of Epidemiology, Mailman School of Public Health, Columbia University, New York,
NY, USA. 10Departments
of Surgery, Immunology and Molecular Genetics and Microbiology, Duke University, Durham, North Carolina, USA.
#
These authors contributed equally to this work.
Author Manuscript
Abstract The impact of topical antiretrovirals for pre-exposure prophylaxis on humoral responses following HIV infection is unknown. Using a binding antibody multiplex assay, we investigated HIV-specific IgG and IgA responses to envelope glycoproteins, p24 Gag and p66 in the genital tract and plasma
Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms Correspondence: D Archary (; Email:
[email protected]) or G Tomaras (; Email:
[email protected]) Conflict of Interest: The authors declare that there is no conflict of interest.
Archary et al.
Page 2
Author Manuscript
following HIV acquisition in women assigned to tenofovir gel (n=24) and placebo gel (n=24) in the CAPRISA 004 microbicide trial to assess if this topical antiretroviral had an impact on mucosal and systemic antibody responses. Linear mixed effect modeling and partial least squares discriminant analysis was used to identify multivariate antibody signatures associated with tenofovir use. There were significantly higher response rates to gp120 Env (p=0.03), p24 (p=0.002) and p66 (p=0.009) in plasma and genital tract (GT) in women assigned to tenofovir than placebo gel at multiple time-points post-infection. Notably, p66 IgA titres in the GT and plasma were significantly higher in the tenofovir compared to the placebo arm (p